Network origin in Marina von Schönau first degree
Entity | Entity type | Industry | |
---|---|---|---|
BioVersys AG
BioVersys AG Miscellaneous Commercial ServicesCommercial Services BioVersys AG operates as a holding company, which specializes in the research and development of small molecules acting on novel bacterial targets. Its research focuses on nosocomial infection and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland.
5
| Holding Company | Miscellaneous Commercial Services | 5 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Marina von Schönau via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Monogram Biosciences, Inc.
Monogram Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Monogram Biosciences, Inc. develops and commercializes diagnostic products for the treatment of human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) infection, and other viral illnesses, as well as cancer and other diseases. It offers HIV tests, including genotypic, phenotypic, tropism, and combined phenotype and genotype assays, suppression management and viral load testing, HCV assays and oncology tests. The company was founded in 1995 and is headquartered in South San Francisco, CA. | Miscellaneous Commercial Services | Director/Board Member | |
CONSORT MEDICAL PLC | Pharmaceuticals: Major | Director/Board Member | |
EVOTEC SE | Pharmaceuticals: Major | Director/Board Member | |
BTG | Pharmaceuticals: Major | Director/Board Member | |
Baumann & Cie KmG
Baumann & Cie KmG Investment ManagersFinance Baumann & Cie KmG provides private banking services. It provides services for private and institutional investors. The company is headquartered in Basel, Switzerland. | Investment Managers | Chief Executive Officer | |
University of Cambridge | College/University | Doctorate Degree | |
University of London | College/University | Graduate Degree | |
ABLYNX | Biotechnology | Director/Board Member | |
Glaxo Group Research Ltd. | Chief Tech/Sci/R&D Officer | ||
William Jenkins Pharma Consulting | Corporate Officer/Principal | ||
Apitope International NV
Apitope International NV BiotechnologyHealth Technology Apitope International NV develops therapeutic vaccines. It operates as a bio-pharmaceutical company that engages in developing peptide therapies. The firm specializes on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves’ disease, FVIII intolerance and uveitis. The company was founded by David Wraith in 2002 and is headquartered in Diepenbeek, Belgium. | Biotechnology | Director/Board Member | |
Apitope Technology (Bristol) Ltd.
Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies. | Miscellaneous Commercial Services | Director/Board Member | |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Allecra Therapeutics GmbH
Allecra Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Allecra Therapeutics GmbH focuses on the development of novel treatments to combat multi drug-resistant bacterial infections. The firm serves the bio and pharmaceutical industry. The company was founded by Nicholas Benedict and Stuart Shapiro in 2013 and is headquartered in Weil am Rhein, Germany. | Pharmaceuticals: Major | Director/Board Member | |
AlloCyte Pharmaceuticals AG
AlloCyte Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology AlloCyte Pharmaceuticals AG develops small molecule drugs for immune-mediated diseases. The private company is based in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Vaximm AG
Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Miscellaneous Commercial Services | Director/Board Member |
Statistics
International
United Kingdom | 7 |
Switzerland | 7 |
United States | 4 |
Netherlands | 3 |
Germany | 3 |
Sectoral
Health Technology | 13 |
Commercial Services | 4 |
Consumer Services | 3 |
Finance | 2 |
Operational
Director/Board Member | 17 |
Independent Dir/Board Member | 5 |
Chief Tech/Sci/R&D Officer | 3 |
Chief Executive Officer | 3 |
Graduate Degree | 2 |
Most connected contacts
Insiders | |
---|---|
William John Jenkins | 20 |
Seng Chin Mah | 2 |
Daniel O.A. Rüedi | 2 |
Marc Gitzinger | 1 |
David Hunstad | 1 |
- Stock Market
- Insiders
- Marina von Schönau
- Company connections